Shang Hai Zheng Quan Bao·2025-11-13 18:27Core Viewpoint - The company, Innovent Biologics, reported significant growth in revenue and improved gross margin for the first nine months of 2025, driven by the sales of its core product, Ibrutinib (Yinokai), and a licensing agreement with Prolium Bioscience Inc. [3][4] Financial Performance - Total revenue for the first nine months of 2025 reached 1.115 billion yuan, a year-on-year increase of 59.85% [3] - Gross margin improved to 88.8%, up from 86.0% in the same period last year, reflecting a 2.8 percentage point increase [3] - The net loss for the same period was 72 million yuan, a reduction of 74.78% compared to the previous year [3] Product Performance - Sales revenue from Ibrutinib (Yinokai) for the first nine months of 2025 was 1.010 billion yuan, representing a year-on-year growth of 45.77% [4] - In April 2025, Ibrutinib received approval for a new indication for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients [4] - Ibrutinib is the first and only BTK inhibitor approved in China for the MZL indication and is included in multiple recommendations in the latest CSCO lymphoma treatment guidelines [4] Cash Position - As of September 30, 2025, the company held approximately 7.759 billion yuan in cash and cash equivalents, enabling it to accelerate the development of its pipeline projects [5] Shareholder Information - As of the reporting period, the total number of shares issued by the company was 1,764,643,952, with 84.79% listed in Hong Kong and 15.21% on the Shanghai Stock Exchange [6][7]